Maze Therapeutics share price logo

Maze Therapeutics Share Price

NASDAQ: MAZE

Small Cap

$23.49

+0.03

(+0.13%)

as on

Maze Therapeutics Stock Performance

as on September 18, 2025 at 1:29 am IST

  • Day's Low

    Day's High

    $22.89
    $24.49
    downward going graph

    2.55%

    Downside

    4.26%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $6.71
    $25.5
    downward going graph

    71.43%

    Downside

    8.56%

    Upside

    downward going graph

Maze Therapeutics share price movements today

Previous Close
$23.46
Open
$22.89
Volume
314.3K
Day's Low - High
$22.89 - $24.49
52 Week Low - High
$6.71 - $25.5

Maze Therapeutics Historical Returns

1 Month Return
+ 73.78 %
3 Month Return
+ 89.35 %
1 Year Return
0 %
3 Year Return
0 %
5 Year Return
0 %

Maze Therapeutics Stock Fundamentals & Key Indicators

Check Maze Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$525.3M

EPS (TTM)

0

Dividend Yield

0.00%

PE Ratio (TTM)

0

P/B Ratio

0

PEG Ratio

0

Return On Equity TTM

1674100.00%

Maze Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Maze Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Maze Therapeutics image
Maze Therapeutics
NA$525.3MNANA32.97%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$60.5B252.04%-505.15-12.96%
Beone Medicines Ltd image
Beone Medicines Ltd
NA$39.0BNANA-3.89%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$100.3B44.17%27.8531.86%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$59.6B1.78%14.131.37%

Maze Therapeutics Stock's Interest Amongst Investors

Search interest for Maze Therapeutics Stock has increased by 18% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:18% versus previous 30 day period

Maze Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Total Revenue
-
-
-
165
2
-
-
-
Gross Profit
-1
0
0
165
2
0
0
0
Operating Income
-25
-23
-28
139
-24
-29
-35
-36
EBITDA
-24
-22
-27
140
-23
-29
-35
-36
Interest Expense
-
-
-
-
-
-
-
-
Depreciation
1
0
0
0
0
0
0
0
Income Before Tax
-24
-26
-32
140
-25
-29
-32
-33
Income Tax Expense
-
-
-
1
0
0
-
-
Net Income
-24
-26
-32
139
-24
-29
-32
-33
Net Profit Margin
0.00%
0.00%
0.00%
84.28%
-990.08%
0.00%
0.00%
0.00%

Maze Therapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2022
Dec 2023
Dec 2024
Total Revenue
-
-
167
Gross Profit
-3
-4
167
Operating Income
-111
-98
57
EBITDA
-107
-94
60
Interest Expense
-
-
-
Depreciation
3
4
3
Income Before Tax
-114
-100
53
Income Tax Expense
-
-
1
Net Income
-114
-100
52
Net Profit Margin
0.00%
0.00%
31.18%

Maze Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Net Income
-26
-32
139
-24
-29
-32
-33
Operating Cash Flow
-20
-23
145
-23
-22
-29
-30
Investing Cash Flow
0
0
0
0
0
0
0
Financing Cash Flow
16
24
0
-2
70
127
0
Change in Cash
-4
0
145
-25
47
97
-29

Maze Therapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2023
Dec 2024
Net Income
-100
52
Operating Cash Flow
-86
75
Investing Cash Flow
0
-1
Financing Cash Flow
16
92
Change in Cash
-70
167

Insights on Maze Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 month, MAZE stock has moved up by 75.7%

About Maze Therapeutics

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.
OrganisationMaze Therapeutics
Headquarters171 Oyster Point Blvd, South San Francisco, CA, United States, 94080
CEODr. Jason V. Coloma M.B.A., M.P.H., Ph.D.
E-voting on sharesClick here to vote

Key Management of Maze Therapeutics

Name

Title

Ms. Courtney J. Phillips J.D.

General Counsel & Corporate Secretary

Mr. Vipin Vijayakumar

Vice President of R&D Infrastructure and Operations

Mr. Matt Krause

Senior Vice President of Human Resources

Mr. Winston Tse

Senior Vice President of Drug Discovery

Ms. Susan Limb

Senior Vice President of Clinical Development

Dr. Jason V. Coloma M.B.A., M.P.H., Ph.D.

CEO & Director

Dr. Harold S. Bernstein M.D., Ph.D.

President of Research & Development and Chief Medical Officer

Mr. Atul Dandekar

Chief Strategy & Business Officer

Ms. Nazila Habibizad

Senior Vice President of Technical Operations & Supply Chain

Mr. Maarten Hoek

Senior Vice President of Research

FAQs

What is Maze Therapeutics share price today?

Maze Therapeutics share price today is $23.49 as on at the close of the market. Maze Therapeutics share today touched a day high of $24.49 and a low of $22.89.

What is the 52 week high and 52 week low for Maze Therapeutics share?

Maze Therapeutics share touched a 52 week high of $25.5 on and a 52 week low of $6.71 on . Maze Therapeutics stock price today i.e. is closed at $23.49,which is 7.88% down from its 52 week high and 250.07% up from its 52 week low.

What is Maze Therapeutics's market capitalisation today?

Maze Therapeutics market capitalisation is $0.00T as on .

How to invest in Maze Therapeutics Stock (MAZE) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Maze Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Maze Therapeutics Shares that will get you 0.0639 shares as per Maze Therapeutics share price of $23.49 per share as on September 18, 2025 at 1:29 am IST.

What is the minimum amount required to buy Maze Therapeutics Stock (MAZE) from India?

Indian investors can start investing in Maze Therapeutics (MAZE) shares with as little as ₹87.816 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹878.16 in Maze Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Maze Therapeutics share’s latest price of $23.49 as on September 18, 2025 at 1:29 am IST, you will get 0.4257 shares of Maze Therapeutics. Learn more about fractional shares .